USE OF R-OXIRACETAM IN PHARMACEUTICAL FIELD

• US 20180147183A1
• Filed: 05/17/2016
• Published: 05/31/2018
• Est. Priority Date: 05/18/2015
• Status: Abandoned Application

• Current Assignee: Chongqing Runze Pharmaceutical Co Ltd
• Original Assignee: Chongqing Runze Pharmaceutical Co Ltd
• Inventors: Ye, Lei
• Application Number:
  US15/574,846
• Publication Number:
  US 20180147183A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/4015 having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61K 9/2018 Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• CPC Class Codes: A61K 9/4858 Organic compounds
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants

Abstract

Provided is a use of R-oxiracetam in the preparation of a drug for preventing or treating epilepsy. An experimental result shows that the R-oxiracetam has an obvious effect in the treatment of generalized epilepsy seizure, partial epilepsy seizure and status epilepticus.

Claims

1. A method of preventing or treating epilepsy, comprising administering to a subject in need a drug comprising a therapeutically effective amount of R-oxiracetam compound, and pharmaceutically acceptable excipients.

6. The method as claimed in claim 1, characterized in that the R-oxiracetam compound or a composition containing the R-oxiracetam compound is administered at a dose of not less than 400 mg/day.

11. The drug as claimed in any one of claim 1, characterized in that the optical purity of the R-oxiracetam compound is 99.0% or more, based on weight percent.

2. A method of preventing or treating acute epilepsy seizure, comprising administering to a subject in need a drug comprising a therapeutically effective amount of R-oxiracetam compound, and pharmaceutically acceptable excipients.

7. The method as claimed in claim 2, characterized in that the R-oxiracetam compound or a composition containing the R-oxiracetam compound is administered at a dose of not less than 400 mg/day.

12. The method as claimed in claim 2, characterized in that the optical purity of the R-oxiracetam compound is 99.0% or more, based on weight percent.

3. A method of preventing or treating generalized epilepsy seizure, comprising administering to a subject in need a drug comprising a therapeutically effective amount of R-oxiracetam compound, and pharmaceutically acceptable excipients.

8. The method as claimed in claim 3, characterized in that the R-oxiracetam compound or a composition containing the R-oxiracetam compound is administered at a dose of not less than 400 mg/day.

13. The method as claimed in claim 3, characterized in that the optical purity of the R-oxiracetam compound is 99.0% or more, based on weight percent.

4. A method of preventing or treating partial epilepsy seizure, comprising administering to a subject in need a drug comprising a therapeutically effective amount of R-oxiracetam compound, and pharmaceutically acceptable excipients.

9. The method as claimed in claim 4, characterized in that the R-oxiracetam compound or a composition containing the R-oxiracetam compound is administered at a dose of not less than 400 mg/day.

14. The method as claimed in claim 4, characterized in that the optical purity of the R-oxiracetam compound is 99.0% or more, based on weight percent.

5. A method of preventing or treating status epilepticus, comprising administering to a subject in need a drug comprising a therapeutically effective amount of R-oxiracetam compound, and pharmaceutically acceptable excipients.

10. The method as claimed in claim 5, characterized in that the R-oxiracetam compound or a composition containing the R-oxiracetam compound is administered at a dose of not less than 400 mg/day.

15. The method as claimed in claim 5, characterized in that the optical purity of the R-oxiracetam compound is 99.0% or more, based on weight percent.